Patricia L Earl

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response
    Patricia L Earl
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:9105-12. 2012
  2. pmc Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously
    Jennifer L Greenier
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Virol J 2:11. 2005
  3. pmc Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate
    Patricia L Earl
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 33, Room 1E19, 33 North Drive, MSC 3210, Bethesda, MD 20892, USA
    Virology 366:84-97. 2007
  4. pmc Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines
    Patricia L Earl
    Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA
    Vaccine 27:5885-95. 2009
  5. pmc Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 3210, USA
    Vaccine 26:486-93. 2008
  6. pmc Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge
    Christiana N Fogg
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892 3210, USA
    J Virol 82:8022-9. 2008
  7. pmc Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges
    Christiana N Fogg
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Vaccine 25:2787-99. 2007
  8. pmc Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus
    Patricia L Earl
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3210, USA
    Proc Natl Acad Sci U S A 105:10889-94. 2008
  9. ncbi request reprint Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    AIDS Res Hum Retroviruses 20:645-53. 2004
  10. pmc Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3210, USA
    J Virol 83:7176-84. 2009

Collaborators

Detail Information

Publications30

  1. pmc Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response
    Patricia L Earl
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    J Virol 86:9105-12. 2012
    ..Furthermore, C57BL/6 mice with inactivation of the IFN-γ gene or the IFN-γ receptor gene exhibited enhanced sensitivity to MPXV...
  2. pmc Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously
    Jennifer L Greenier
    California National Primate Research Center, University of California, Davis, CA 95616, USA
    Virol J 2:11. 2005
    ..J. Virology 77:179-190, 2003). Here we evaluate the impact of these vaccines on oral transmission and evolution of SIV envelope variants...
  3. pmc Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate
    Patricia L Earl
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 33, Room 1E19, 33 North Drive, MSC 3210, Bethesda, MD 20892, USA
    Virology 366:84-97. 2007
    ..These non-human primate studies support the clinical testing of recombinant MVA as an HIV vaccine and further demonstrate that MVA can provide long-term poxvirus immunity, essential for use as an alternative smallpox vaccine...
  4. pmc Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines
    Patricia L Earl
    Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA
    Vaccine 27:5885-95. 2009
    ..The MVA/CMDR vaccine candidate expressing CRF01_AE genes has elicited HIV-specific T-cell responses in two independent Phase I clinical trials. Further testing of the other rMVA is warranted...
  5. pmc Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 3210, USA
    Vaccine 26:486-93. 2008
    ..These data suggest that for high immunogenicity, rMVAs should be engineered to produce the most recombinant protein that can be achieved without compromising the growth and stability of the rMVA...
  6. pmc Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge
    Christiana N Fogg
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland 20892 3210, USA
    J Virol 82:8022-9. 2008
    ..These studies raise questions regarding the basis for antibody protection against poxvirus disease and highlight the importance of animal models for the early evaluation of vaccine candidates...
  7. pmc Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges
    Christiana N Fogg
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Vaccine 25:2787-99. 2007
    ....
  8. pmc Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus
    Patricia L Earl
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3210, USA
    Proc Natl Acad Sci U S A 105:10889-94. 2008
    ..Protection correlated with the more rapid immune response to MVA compared to Dryvax, which may be related to the higher dose of MVA that can be tolerated safely...
  9. ncbi request reprint Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    AIDS Res Hum Retroviruses 20:645-53. 2004
    ..In the accompanying paper, we show that MVA/HIV 48 provided efficient boosting of an HIV DNA vaccine...
  10. pmc Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3210, USA
    J Virol 83:7176-84. 2009
    ..Understanding the causes of instability and taking preemptive actions will facilitate the development of rMVA and other poxviruses as human and veterinary recombinant vaccines...
  11. pmc Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0445, USA
    Proc Natl Acad Sci U S A 101:4590-5. 2004
    ..This study confirmed the safety of MVA and demonstrated that the overlapping immune responses protected normal and partially immune-deficient animals, an encouraging result for this candidate attenuated smallpox vaccine...
  12. pmc Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA
    Linda S Wyatt
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 372:260-72. 2008
    ..Thus, truncation of Env enhanced genetic stability as well as serum and mucosal antibody responses, suggesting the desirability of a similar modification in MVA-based candidate HIV vaccines...
  13. pmc Identification of wild-derived inbred mouse strains highly susceptible to monkeypox virus infection for use as small animal models
    Jeffrey L Americo
    Laboratory of Viral Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 84:8172-80. 2010
    ....
  14. pmc Elimination of A-type inclusion formation enhances cowpox virus replication in mice: implications for orthopoxvirus evolution
    Robin J Kastenmayer
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 33 North Drive, MSC 3210, Bethesda, MD 20892 3210, USA
    Virology 452:59-66. 2014
    ..Deletion of the gene for embedding virions had a lesser effect, possibly due to known additional functions of the encoded protein. ..
  15. ncbi request reprint Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox
    Patricia L Earl
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 0445, USA
    Nature 428:182-5. 2004
    ....
  16. pmc Susceptibility of the wild-derived inbred CAST/Ei mouse to infection by orthopoxviruses analyzed by live bioluminescence imaging
    Jeffrey L Americo
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Virology 449:120-32. 2014
    ..The spreading kinetics was more rapid with VACV than CPXV although the peak photon flux was similar. These data suggest advantages of CAST/Ei mice for orthopoxvirus studies. ..
  17. pmc Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens
    Silvia Ratto-Kim
    United States Military HIV Research Program, Walter Reed Army Institute of Research, Rockville, Maryland, USA
    PLoS ONE 7:e45840. 2012
    ..This study supports the rationale for testing heterologous prime-boost regimens in humans...
  18. ncbi request reprint Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model
    Patricia L Earl
    Laboratory of Viral Diseases, National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 20892, USA
    Virology 294:270-81. 2002
    ..Thus, immunization with MVA/SHIV89.6 alone or with a protein boost stimulated both arms of the immune system and resulted in significant control of viremia and delayed progression to disease after challenge with SHIV-89.6P...
  19. doi request reprint Overview of the vaccinia virus expression system
    Bernard Moss
    National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
    Curr Protoc Mol Biol . 2002
    ..The vaccinia vector expression system is described along with specific steps for expressing genes using these vectors. Important safety considerations are also presented...
  20. pmc Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein
    Patricia L Earl
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 0445, USA
    J Virol 77:10684-8. 2003
    ..Here we describe the development and use of a 96-well plate, semi-automated, flow cytometric assay that uses a recombinant vaccinia virus expressing enhanced green fluorescent protein and which would be applicable to other viruses...
  21. pmc Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface
    Rob J Center
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 76:7863-7. 2002
    ..These results, which firmly establish the oligomeric structure of human immunodeficiency virus virion-associated Env, parallel those of our previous analysis of the simian immunodeficiency virus Env...
  22. pmc Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine
    Rama Rao Amara
    Vaccine Research Center, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Virol 76:6138-46. 2002
    ..Our results highlight the importance of immune responses to Env, as well as to Gag-Pol, in the control of immunodeficiency virus challenges and the protection of CD4(+) cells...
  23. pmc Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines
    Rama Rao Amara
    Vaccine Research Center and Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia 30329, USA
    J Virol 76:7625-31. 2002
    ..Thus, MVA vaccines, as well as DNA/MVA vaccines, merit further evaluation for their ability to control the current AIDS pandemic...
  24. ncbi request reprint Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine
    Harriet L Robinson
    Emory Vaccine Center of Emory University School of Medicine, Atlanta, GA 30322, USA
    Virology 352:285-94. 2006
    ..The GM-CSF-adjuvanted group showed a trend towards better control of the challenge infection and had better control of re-emergent virus (P < 0.01) than the non-adjuvanted group...
  25. ncbi request reprint Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge
    Suzan L Buge
    Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, USA
    AIDS Res Hum Retroviruses 19:891-900. 2003
    ..This trend did not reach significance in our animal groups of 8. We conclude that gp120 inoculations that fail to raise neutralizing antibody do not improve the efficacy of Gag-Pol-Env DNA/MVA vaccines...
  26. ncbi request reprint Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques
    James M Smith
    Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia 30329, USA
    AIDS Res Hum Retroviruses 20:654-65. 2004
    ....
  27. pmc DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge
    Pragati Nigam
    Emory Vaccine Center, Department of Microbiology and Immunology, and Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, NE, Atlanta, GA 30329, USA
    Virology 366:73-83. 2007
    ..Thus, our results demonstrate the elicitation of long lasting protective immunity for a lethal monkeypox challenge by a DNA/MVA HIV-1 vaccine...
  28. ncbi request reprint Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    Rama Rao Amara
    Vaccine Research Center, Yerkes Regional Primate Research Center, Emory University, 954 Gatewood Road NE, Atlanta, GA 30329, USA
    Vaccine 20:1949-55. 2002
    ..These highly promising findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the AIDS epidemic...
  29. pmc Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax
    D Huw Davies
    University of California Irvine, Department of Medicine Division of Infectious Diseases, 3501 Hewitt Hall, Irvine, CA 92697, USA
    J Virol 82:652-63. 2008
    ..The work supports other information suggesting that MVA may be a useful alternative to Dryvax...
  30. pmc Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains
    Paolo Lusso
    Unit of Human Virology, Department of Biological and Technological Research DIBIT, San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy
    J Virol 79:6957-68. 2005
    ....